Trust, there are now published data to suggest that such an approach can be both clinically effective and cost-effective. 1, 11 For the present time, we have not made further alterations to our prophylaxis regimen. Although many centres do not use metronidazole, this agent remains 'for consideration' in the EAU guidelines 6 and probably prevents anaerobic microabscess formation within the prostate and, hence, more chronic/low-grade infective problems.
Sir, Cardiovascular diseases (CVDs) and bone mineral disorders are two frequent ageing-related complications in HIV-infected subjects. These diseases share common pathophysiological mechanisms, suggesting interplay between bone cells and the vascular system; 1,2 therefore, bone-secreted substances may also play a role in the occurrence of CVD.
Fibroblast growth factor (FGF)-23, recently identified as a hormone, is produced in bone by osteocytes and circulates in the bloodstream to regulate phosphate handling and vitamin D production in the kidney through a specific receptor. Higher FGF-23 levels are associated with increased CVD events in patients with chronic kidney disease 3 and in the general population. 4, 5 Osteocalcin is a bone-specific protein produced by mature osteoblasts, is stored in the bone matrix and is released into the circulation during bone resorption. Reduced levels of total osteocalcin are associated with adiposity, insulin resistance and type 2 diabetes, 6 implying this bone-derived peptide might modulate cardiovascular risk (CVR). 7 Data on the association of FGF-23 and osteocalcin with CVR in HIV-infected subjects are limited. The following cross-sectional study has therefore been designed with the aim to assess these associations in HIV-infected subjects.
HIV-infected males on antiretroviral (ARV) treatment, followed at the Infectious Diseases Department of the San Raffaele Scientific Institute, were classified according to their 10 year Framingham CVR score (.20% and ≤20%). Patients with a CVR score .20% were matched, in a ratio 1 : 2, by year of HIV infection (+1 year) and year of ARV exposure (+1 year) with subjects with a CVR score ≤20%. Obesity was defined as a body mass index (BMI Blood and 24 h urinary samples were taken to determine FGF-23 and bone metabolism markers. Clearance creatinine was calculated on the 24 h urinary creatinine value, plasma creatinine, 24 h urine volume and adjusted for body surface area. FGF-23 plasma levels were determined using Human Intact FGF-23 ELISA (Immutopics). This study was approved by San Raffaele Scientific Institute's Institutional Review Board. Patients signed a written informed consent form before participation in the study.
The results are described as the median (IQR). Logistic regression was applied: the characteristics associated with a P value ,0.15 in the univariate analysis (age, BMI, systolic blood pressure, osteocalcin, FGF-23, creatinine clearance, 24 h urinary phosphate and HOMA-IR) were entered into the model to evaluate their association with an elevated CVD risk.
The parameters that were correlated, clearly indicating multicollinearity [triglycerides were correlated with osteocalcin values (r ¼ 20.33, P ¼0.021] and high-density lipoprotein (HDL) cholesterol was correlated with FGF-23 values (r ¼20.311, P ¼ 0.030)] were not entered in the multivariate model.
Fifty-one patients were included. The patients' characteristics according to CVR score are described in Table 1 .
Univariate and multivariate logistic regression analyses are reported in Table 2 .
In the multivariate analysis, a CVR score .20% was associated with FGF-23 levels (OR ¼ 2.296 per 10 RU/mL higher, 95% CI: 1.105-8.037; P ¼ 0.048) and osteocalcin levels (OR ¼ 0.011 per 10 ng/mL higher, 95% CI: 0.001 -0.262; P ¼0.048), while no association was found between a CVR score .20% and age, BMI, systolic blood pressure, creatinine clearance, 24 h urinary phosphate or HOMA-IR.
We found that high plasma levels of FGF-23 and low serum levels of osteocalcin were independently associated with a 10 year CVR score .20% in HIV-infected subjects. The mechanisms responsible for this association are uncertain, but different hypotheses have been tested.
The current understanding of FGF-23 and CVR mainly relates to the role of FGF-23 in mineral metabolism: higher FGF-23 levels are associated with higher serum phosphorus levels, which in turn are associated with vascular calcification and CVD events. 10 There is evidence for a graded relationship between FGF-23 and the severity of atherosclerosis, 11 consistent with the findings that higher FGF-23 associates with endothelium dysfunction, which has been shown to precede the development of atherosclerosis and predict future cardiovascular outcomes. 12 In addition, because active vitamin D regulates the renin -angiotensin axis and the proliferation of cardiomyocytes, FGF-23 may also affect the cardiovascular system through its inhibition of vitamin D activation. 13 The relationship between FGF-23 and CVR may, in part, also be mediated through classical risk factors, beyond mineral metabolism, such as obesity and dyslipidaemia. 14 Finally, higher age, BMI, phosphorus intake, current smoking, higher parathyroid hormone, phosphate, triglyceride and uric acid levels, some biomarkers of inflammation and a history of hypertension were independently associated with higher plasma FGF-23 concentrations. 15 In our study, low serum levels of osteocalcin were associated with a CVR score .20%. Previous large observational studies 6 There is accumulating evidence suggesting that osteocalcin is associated with glucose and fat metabolism via modulation of insulin and adiponectin secretion, which might, in turn, affect the cardiovascular system as well as subsequent fatal events. 16 Osteocalcin might also cross-talk directly via angiotensin II and Toll-like receptor 4 with the vascular system and contribute to vascular remodelling. 17 Thus, osteocalcin might be indicative of CVD and mortality.
We report, for the first time, independent associations between higher circulating FGF-23 and lower osteocalcin serum levels with a 10 year CVR score .20%. These findings add to the growing body of literature demonstrating that abnormalities in mineral metabolism may identify HIV-infected subjects at greater CVR. Additional studies that evaluate the predictive power of FGF-23 and osteocalcin and whether these biomarkers have further clinical implications are needed.
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